Nilotinib leukaemia drug binding to its target, the enzyme Bcr-Abl tyrosine kinase. This enzyme is produced by a genetic mutation, the swapping of parts of two chromosomes, leading to the formation of the oncogene (cancer-causing gene) Bcr-Abl, which produces a constantly-active version of normal Abl tyrosine kinase. This causes chronic myelogenous leukaemia (CML), a cancer of white blood cells. The drug Tasigna (Nilotinib) works by binding to the active site of the Bcr-Abl enzyme, producing a change in shape that prevents the enzyme from functioning. This causes the death of cancerous cells expressing the enzyme. Tasigna is marketed by Novartis. | |
Lizenzart: | Lizenzpflichtig |
Credit: | Science Photo Library / Andrade, Ramon / 3dciencia |
Modell-Rechte: | nicht erforderlich |
Eigentums-Rechte: | nicht erforderlich |
Länge: | 10 Sekunden |
Seitenverhältnis: | 16:9 |
Restrictions: | - |